Compare Strategy Inc. (MSTR) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Strategy Inc. trades at $140.79 (market cap $64.44B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Strategy Inc. is far larger — about 8.6× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Strategy Inc. for 113 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MSTR | SYRE | |
|---|---|---|
Market Cap | $64.44B | $7.52B |
Volume | 12,273,653 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $301.91 | $108.92 |
52-Week Low | $82.31 | $22.18 |
Typical Hold Time | 113 Days | 0 Days |
Enterprise Value | $83.20B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR stock trades at $143.24, down 6.18% today, with technical indicators showing neutral momentum near key support at $142. The company reported Q2 2026 EPS of -$24.45, missing expectations of -$2.19, continuing a trend of significant earnings misses. Despite negative profitability metrics including a -6,102.96% net income margin, analyst consensus remains bullish with 62% buy ratings and a $253.36 price target representing 77% upside potential from current levels.
The investment case hinges on analyst optimism despite fundamental challenges, with Citigroup recently doubling its price target to $240. Key risks include persistent negative earnings, high valuation multiples (P/S of 96.6), and substantial debt load of $7.19 billion. Cash flow trends show heavy reliance on financing activities to support operations and investments.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
